Barclays Maintains Overweight on Regenxbio, Raises Price Target to $82
Barclays analyst Gena Wang maintains Regenxbio (NASDAQ:RGNX) with a Overweight and raises the price target from $79 to $82.
Related Posts
Wells Fargo Maintains Overweight on Flywire, Raises Price Target to $30
Wells Fargo analyst Jeff Cantwell maintains Flywire (NASDAQ:FLYW) with a Overweight and raises the price target from $27 to $30.
BMO Capital Upgrades Riocan REIT to Outperform, Raises Price Target to $24
BMO Capital analyst Jenny Ma upgrades Riocan REIT (OTC:RIOCF) from Market Perform to Outperform and raises the price target from $21 to $24.
Stephens & Co. Reiterates Overweight on Performance Food Gr, Maintains $68 Price Target
Stephens & Co. analyst Joshua Long reiterates Performance Food Gr (NYSE:PFGC) with a Overweight and maintains $68 price target.